地塞米松植入剂主动治疗方案用于糖尿病性与视网膜静脉阻塞性黄斑水肿:ProDEX-2研究
PURPOSE: To evaluate the efficacy of proactive treatment with intravitreal dexamethasone implant (DEX-implant) at fixed 4-month intervals in treatment-naïve patients with diabetic macular oedema (DMO) and retinal vein occlusion (RVO), stratified by baseline visual acuity.…
要点
- 每4个月固定注射地塞米松植入剂可显著改善未治疗糖尿病性与视网膜静脉阻塞性黄斑水肿的视力和解剖结构。
- 基线视力较低者(<55个ETDRS字母)视力改善(+8.5±7.8字母)大于基线视力较高者(+2.7±6.1字母,p=0.004)。
- 基线高反射灶数量是视力改善的最强正向预测因子(β=0.24,p<0.001),年龄较大呈负相关(每10年β=-0.14,p=0.018)。
核心结论
- 地塞米松植入剂主动治疗使未治疗糖尿病性与视网膜静脉阻塞性黄斑水肿患者获得显著功能和解剖改善,并防止视力和中央亚区视网膜厚度波动。
研究设计与样本
- 患者按基线视力<55 vs ≥55个ETDRS字母分层,主要结局为12个月时视力、中央亚区视网膜厚度、黄斑水肿复发率和OCT定性参数变化。
主要发现
- 12个月时平均视力从51.9±21.1提高到57.8±15.7个ETDRS字母(p<0.001)。
- 基线视力较低者视力改善+8.5±7.8个字母,基线视力较高者改善+2.7±6.1个字母(p=0.004)。
- 平均中央亚区视网膜厚度从549.5±196.4微米降至388.0±158.7微米(p<0.001)。
- 12个月时47.5%的眼维持最佳或优秀解剖反应,允许标准或延长治疗间隔。
- 多因素分析显示基线高反射灶数量是视力改善的最强正向预测因子(β=0.24,p<0.001),年龄较大呈负相关(每10年β=-0.14,p=0.018)。
临床怎么用
- 对未治疗糖尿病性与视网膜静脉阻塞性黄斑水肿可考虑每4个月固定注射地塞米松植入剂并根据解剖反应调整间隔的主动治疗策略。
- 基线视力较低和高反射灶数量较多的患者可能从该方案中获得更大视力改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy of proactive treatment with intravitreal dexamethasone implant (DEX-implant) at fixed 4-month intervals in treatment-naïve patients with diabetic macular oedema (DMO) and retinal vein occlusion (RVO), stratified by baseline visual acuity. METHODS: Sixty-one treatment-naïve eyes (35 DMO, 26 RVO) received DEX-implant at 4-month intervals with possible adjustment (3.5-4.5 months) based on anatomical response. Patients were stratified by baseline visual acuity (<55 vs ≥55 Early Treatment Diabetic Retinopathy Study (ETDRS) letters). Main outcomes included changes in visual acuity, central subfield retinal thickness (CST), macular oedema recurrence rates and OCT qualitative parameters at 12 months. RESULTS: Mean visual acuity improved from 51.9±21.1 to 57.8±15.7 ETDRS letters at month 12 (p<0.001). Patients with lower baseline visual acuity showed greater improvement (+8.5±7.8 letters) compared with those with higher baseline acuity (+2.7±6.1 letters, p=0.004). Mean CST decreased from 549.5±196.4 µm to 388.0±158.7 µm (p<0.001). At month 12, 47.5% of eyes maintained optimal or excellent anatomical response, allowing standard or extended intervals. The proactive approach prevented visual acuity and CST fluctuations. Multivariate analysis identified baseline hyperreflective foci count as the strongest positive predictor of visual improvement (β=0.24, p<0.001), while older age was negatively associated (β=-0.14 per 10 years, p=0.018). CONCLUSIONS: Proactive treatment with DEX-implant provided significant functional and anatomical improvements in treatment-naïve DMO and RVO patients while preventing deleterious visual acuity and CST fluctuations. Patients with lower baseline visual acuity and higher hyper-reflective foci count demonstrate greater potential for improvement, supporting this approach as an effective strategy, particularly in these subgroups.
引用
- Viggiano P, Peto T, Pignataro M, et al. Proactive treatment regimen with dexamethasone implant for diabetic and post-occlusive macular oedema: the ProDEX-2 study. Br J Ophthalmol. 2026. PMID: 42248659. doi:10.1136/bjo-2025-328550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。